Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
14.72 K
Value Traded
31.45 K
Short % Float
0.47%
Days to Cover
1.0
-10.26%Week
-33.65%1 Month
-56.16%3 Month
-65.46%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.02 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
5.73 M
Float Shares
4.64 M
Insiders
18.98%
Institutions
10.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
OPTH Catalyst Timeline
Dated clinical, regulatory and corporate events for Optimi Health Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Optimi Health Corp.
30Total events
11Upcoming
2Tier-1 (high impact)
2025 to 2027Coverage
Upcoming catalysts 2
Event history 12
▲Manufacturing MilestoneMDMACMC / Inspection
Optimi completes MDMA finished drug product production batch at GMP facility
PTSDsource ↗
●Management ChangeCorporate
Leah Hodges resigns as Corporate Secretary; Dane Stevens appointed to fill role
▲Manufacturing MilestoneCMC / Inspection
Completion and quality release of 5mg naturally derived psilocybin capsule batch at cGMP Princeton facility
major depressive disordersource ↗
●Management ChangeCorporate
Appointment of Michael Blough, Ph.D. as Chief Clinical Development Officer
▲Trial Authorization (CTA / IND)psilocybinEx-US Regulatory
Health Canada authorizes Phase 2 psilocybin-assisted therapy trial in MDD
Major Depressive Disordersource ↗
●ATM ProgramCorporate
Optimi Health establishes US$100 million equity line of credit with Seven Knots
●Equity OfferingCorporate
Issuance of US$1.5 million convertible promissory note to Seven Knots
▲Product LaunchPost-Market
Third commercial shipment of 5mg psilocybin capsules to Australia
treatment-resistant depressionsource ↗
▲Other Regulator MilestonepsilocybinEx-US Regulatory
Updated Authorized Prescriber framework expanded therapist eligibility and treatment settings
treatment-resistant depressionsource ↗
▲Other Regulator MilestoneMDMAEx-US Regulatory
MAPS Israel PTSD clinical trial receives formal approval from Israeli Ministry of Health
PTSDsource ↗
Past FDA Catalysts and PDUFA Decisions
How OPTH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every OPTH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in OPTH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in OPTH for Q2 2026. | ||||
Ownership Trends
OPTH Short Interest
Shares sold short, counted twice a month.
0.47%
Short % of Float
of tradable shares sold short
21.6K
Shares Sold Short
-15.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
24.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OPTH ranks across every disease it competes in
Competitive Position is a premium feature
See how OPTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOPTH News
-OPTH
Oct 26, 2026Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
Optimi Health Corp. has launched Optimi Australia Pty Ltd, a subsidiary for distribution in Australia. Adrian Jones has been appointed as Director of Australian Operations. The subsidiary will manage sales and prescriber relationships for Optimi's psilocybin and MDMA products under Australia's Authorised Prescriber Scheme. The company anticipates increasing demand for its therapies.
Read more →-OPTH
Oct 20, 2026Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Optimi Health completed an MDMA batch for a Canadian Phase 3 PTSD trial, an Israeli study, and Australian commercial supply. The Canadian trial targets veterans and frontline workers, starting in 2027. Australian shipments are planned before year-end 2026. The drug lacks Health Canada market authorization.
Read more →-OPTH
Oct 7, 2026Optimi Health to Present at the ThinkEquity Conference
Optimi Health Corp. will present at the ThinkEquity Conference on October 15, 2026, in New York City. The company plans to provide a corporate overview and hold one-on-one meetings with investors. Optimi is recognized for its GMP-grade psychedelic drug products aimed at mental health therapies, with operations in Canada and Australia.
Read more →-OPTH
Sep 29, 2026Optimi Health Appoints Melanie Pump to Board of Directors
Optimi Health Corp. has appointed Melanie Pump to its Board of Directors, bringing over 25 years of financial expertise. Pump's experience in technology and growth companies is expected to enhance Optimi's strategic direction in the psychedelic pharmaceutical market. The company also announced the resignation of Leah Hodges as Corporate Secretary, with CEO Dane Stevens taking over the role.
Read more →-OPTH
Sep 23, 2026Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
Optimi Health Corp. has completed the production of 5mg psilocybin capsules for a Phase 2 clinical trial approved by Health Canada, aimed at treating major depressive disorder (MDD). The trial will involve up to 200 participants, with dosing expected to conclude by the end of 2027. The same batch will also supply licensed clinics in Australia for treatment-resistant depression. Despite the progress, no psilocybin products have received market authorization yet.
Read more →-OPTH
Sep 22, 2026Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Optimi Health Corp. has appointed Dr. Michael Blough as Chief Clinical Development Officer. Dr. Blough will oversee the company's clinical development strategy, including upcoming Phase 2 and Phase 3 trials for psilocybin and MDMA-assisted therapies. His extensive experience with Health Canada and psychedelic trials positions him to advance these critical studies.
Read more →-OPTH
Sep 16, 2026Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Optimi Health Corp. plans to launch a Phase 3 clinical trial for MDMA-assisted therapy aimed at treating post-traumatic stress disorder (PTSD). The trial, expected to start in 2027, will involve up to 100 participants, primarily veterans and frontline workers. The study will assess the therapy's efficacy using the Clinician-Administered PTSD Scale. Despite the promise of psychedelic-assisted therapies, the safety and efficacy of MDMA for PTSD remain under investigation.
Read more →-OPTH
Sep 10, 2026Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Optimi Health Corp. plans to initiate a Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD) in 2027. The trial will involve up to 200 participants across Canada and aims to assess the safety and efficacy of a single supervised dose of natural psilocybin. This study represents a significant commitment for Optimi, which will utilize its own manufactured psilocybin and aims for exclusive ownership of the trial results.
Read more →-OPTH
Sep 8, 2026Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Optimi Health Corp. (Nasdaq: OPTH) will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The company will provide a presentation on demand starting September 11, and management will be available for one-on-one meetings. Optimi specializes in manufacturing GMP-grade psychedelic drug products for mental health therapies.
Read more →-OPTH
Aug 14, 2026Optimi Health Establishes Discretionary Equity Facility
Optimi Health Corp. has established a discretionary equity line of credit with Seven Knots, allowing the company to sell up to $100 million in common shares. The agreement includes convertible promissory notes and is subject to market conditions and regulatory approvals. This move aims to bolster the company's financial flexibility as it continues to manufacture psychedelic drug products for mental health therapies.
Read more →-OPTH
Jun 29, 2026▲ +8.8%on this news· ran to +24% by day 1
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Corp. has completed its third export of 5mg psilocybin capsules to Australia for patients with treatment-resistant depression. The capsules are prescribed under Australia's Authorized Prescriber Scheme, which has expanded access to psilocybin as a treatment. Optimi's production is fully compliant with Health Canada regulations, and the company reports no serious adverse events since the product's launch.
Read more →-OPTH
Jun 16, 2026▼ -12.9%on this news
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Optimi Health has launched two new microdose psilocybin products, available in 1mg and 2mg dosages, aimed at clinical research organizations. These products provide consistent, validated doses, addressing variability in traditional microdosing methods. The company continues to expand its psilocybin offerings, which are already prescribed for treatment-resistant depression in Australia.
Read more →-OPTH
Jun 10, 2026Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Corp. has completed its first export of psilocybin to the UK to support a Phase 2 clinical trial. The shipment includes psilocybin biomass and 5mg capsules, which are already used in Australia for treatment-resistant depression. The company plans to announce its trial partner and indication later. This export positions Optimi as a key player in regulated psychedelic research.
Read more →-OPTH
Jun 8, 2026▲ +11.2%on this newsshared move
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Corp. has secured a supply of ibogaine and is set to begin development of finished drug products at its GMP facility in British Columbia. The U.S. Executive Order prioritizing ibogaine for FDA review has heightened interest in its therapeutic potential for conditions like PTSD and opioid use disorder. The company plans to offer ibogaine in two dosage forms, 50mg and 100mg, and aims to standardize pharmaceutical dosages.
Read more →-OPTH
Jun 2, 2026Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi Health Corp. has successfully completed a GMP production run of its 5mg psilocybin capsules, which are prescribed for treatment-resistant depression in Australia. The company plans to use additional products from this run for clinical trials in the US and Europe. Optimi's facility is fully compliant with Health Canada regulations, allowing for secure production and distribution of psychedelic drug products.
Read more →-OPTH
May 29, 2026▲ +5.6%on this newsshared move
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Optimi Health Corp. has welcomed the Therapeutic Goods Administration's updated framework in Australia, which expands access to psychedelic-assisted therapy. The new guidelines broaden therapist eligibility and treatment settings, reinforcing Australia's position as a leader in this field. Importantly, no serious adverse events have been reported since the program's inception, supporting further expansion.
Read more →-OPTH
May 29, 2026▲ +5.6%on this newsshared move
OPTIMI HEALTH CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS Overview This management's discussion and analysis (" MD&A ") relates to the operations and financial condition of Optimi Health Corp. (" Optimi " or the " Company
Optimi Health Corp. provided a detailed management discussion and analysis of its financial condition and operations as of May 29, 2026. The company highlighted its licensing under Health Canada for the production of psilocybin and MDMA, enabling it to supply these substances under strict regulatory frameworks. Notably, Optimi has engaged in a distribution agreement with Mind Medicine Australia, facilitating access to its products in the Australian market. The discussion also outlined ongoing investments in research and development to enhance production methodologies.
Read more →-OPTH
May 26, 2026Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Optimi Health Corp. has achieved a milestone by producing the highest-purity natural psilocybin extract to date, which contains 6% psilocybin. This advancement supports their efforts in supplying psilocybin products in Australia for patients with treatment-resistant depression under the Authorized Prescriber Scheme. The company maintains a diverse library of over 200 mushroom genetics, allowing continuous improvement in psilocybin content through optimized cultivation and extraction processes. Optimi's products are also set to aid clinical research in Europe, with a focus on providing finished drug products for various therapeutic programs.
Read more →-OPTH
May 29, 2024Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
Optimi Health Corp. has secured an import permit from Mind Medicine Australia to export GMP MDMA and psilocybin capsules for therapeutic use. This allows Australian psychiatrists to prescribe these substances under the Authorised Prescriber Scheme. The company plans to launch a Prescriber Portal to assist over 2,800 psychiatrists with the import process.
Read more →-OPTH
May 22, 2024Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Optimi Health Corp. has signed a Letter of Intent with ATMA Journey Centers to supply GMP psilocybin for a Phase II clinical trial targeting Major Depressive Disorder. This partnership aims to enhance the accessibility of psilocybin-assisted therapy through group administration protocols. The agreement also includes plans for future Phase III trials in 2025.
Read more →About Optimi Health Corp.
BIOPHARMAWATCH ELITE
Trade the next OPTH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime